Current and future therapeutic approaches for the treatment of small cell lung cancer

被引：37

作者：

Rossi, Antonio ^{[1
]}

Tay, Rebecca ^{[2
]}

Chiramel, Jaseela ^{[2
]}

Prelaj, Arsela ^{[2
,3
]}

Califano, Raffaele ^{[2
,4
,5
]}

机构：

[1] Sci Inst Res & Hlth Care IRCCS Casa Sollievo dell, Div Med Oncol, San Giovanni Rotondo, Italy

[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[3] Sapienza Univ Rome, Dept Radiol Pathol & Oncol Sci, Rome, Italy

[4] Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[5] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2018年 / 18卷 / 05期

关键词：

Durvalumab; immunotherapy; ipilimumab; nivolumab; pembrolizumab; rovalpituzumab tesirine; SCLC; second-line; targeted therapy; tremelimumab; PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; ANTIBODY-DRUG CONJUGATE; DOUBLE-BLIND; OPEN-LABEL; 2ND-LINE TREATMENT; THORACIC RADIOTHERAPY; 1ST-LINE TREATMENT;

D O I：

10.1080/14737140.2018.1453361

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC.Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC.Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.

引用

页码：473 / 486

页数：14

共 50 条

[1] Future directions in therapeutic approaches for small cell lung cancer
Bunn, PA
SEMINARS IN ONCOLOGY, 1996, 23 (06) : 136 - 138
[2] Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived
不详
CURRENT PROBLEMS IN CANCER, 2012, 36 (03) : 156 - 173
[3] Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer
Davies, A
Gandara, DR
Lara, P
Goldberg, Z
Roberts, P
Lau, D
SEMINARS IN ONCOLOGY, 2002, 29 (03) : 10 - 16
[4] INNOVATIVE AND FUTURE APPROACHES TO SMALL CELL LUNG-CANCER TREATMENT
BECK, LK
KANE, MA
BUNN, PA
SEMINARS IN ONCOLOGY, 1988, 15 (03) : 300 - 314
[5] The current role and future prospects of paclitaxel in the treatment of small cell lung cancer
Hainsworth, JD
Greco, FA
SEMINARS IN ONCOLOGY, 1999, 26 (01) : 60 - 66
[6] Non-small cell lung cancer: current treatment and future advances
Zappa, Cecilia
Mousa, Shaker A.
TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (03) : 288 - 300
[7] Therapeutic approaches for patients with small cell lung cancer (SCLC)
Spelda, S
Kaplanová, J
Skricková, J
Dusek, L
Svobodník, A
Dolezal, L
LUNG CANCER: CURRENT TOPICS, 2001, : 215 - 218
[8] Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Rice, Shawn J.
Miller, Bruce
Wagman, Matthias
Jamorabo, Daniel S.
Liu, Xin
Belani, Chandra P.
CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 183 - 195
[9] PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
Barayan, Ranya
Ran, Xiaozhuo
Lok, Benjamin H.
JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6240 - 6252
[10] MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Cortinovis, D.
Monica, V.
Pietrantonio, F.
Ceresoli, G. L.
La Spina, C. M.
Wannesson, L.
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (24) : 3982 - 3990

← 1 2 3 4 5 →